MAIDSTONE, U.K. - s4story -- Bedfont^® Scientific Ltd., a world leader in breath analysis, has been designing and manufacturing medical breath analysis devices for almost 50 years and has seen significant growth over the past decade. The innovative med-tech company is pleased to add further experience to its board of directors with the appointment of Michael Bencak. Michael has over 20 years of experience building and leading companies in the global life science and healthcare industries. His strategic approach helps businesses unlock their potential growth and lead them through international expansion.

Bedfont^® works with healthcare professionals worldwide to provide cutting-edge breath analysis medical products to the highest standard, through technical innovation and professional business practice. Working with over 100 distributors worldwide, Bedfont® is leading the way in breath analysis, thanks to its innovative non-invasive devices that aid diagnosis and investigations, ultimately improving patient care worldwide.

More on S For Story

• High-Growth Power Infrastructure Play Targets AI Boom: 1606 Corp. Executes Aggressive Texas Expansion Strategy: 1606 Corp. (Stock Symbol: CBDW) $CBDW
• Accelerating the Transformation into a U.S. Nuclear Fuel Cycle Leader: Frontier Nuclear and Minerals Inc. (N A S D A Q: FNUC)
• Ozz Metals Ltd Secures 1-Tonne Gold Offtake Agreement
• Owl Publishers Expands Support for Authors with Complete Book Publishing Services
• Jet Set: The Ultimate Coachella Afterparty

"We are delighted to announce the appointment of Michael Bencak to the Board of Bedfont^® Scientific Ltd. Michael brings a wealth of international experience in the medical device and life sciences sectors, with a strong track record of scaling businesses, building global partnerships, and driving strategic growth. His insight and leadership will be invaluable as Bedfont^® continues its mission to advance breath analysis technology and improve patient care worldwide." Said Jason Smith, CEO at Bedfont^®, "As we enter an exciting new phase of growth, Michael's appointment strengthens our Board and supports our long-term strategy to expand Bedfont's global impact in respiratory diagnostics and beyond. Please join us in welcoming Michael to the Bedfont® Board."

With Keensight's acquisition of a majority stake in the business back in 2025, the addition of Michael's experience can only accelerate Bedfont's growth and move it closer to a world where everyone has access to instant, non-invasive, simple breath testing to aid medical diagnosis.

To learn more about Bedfont^® and how it is improving accessibility and healthcare standards worldwide, visit the website here (https://www.bedfont.com/).